Compelling clinical trial data and decisions from the FDA could send one, two, or all three of the biotech stocks highlighted in today’s article through the roof next year. For a look at each of these three biotech stocks and their respective catalysts – as well as a consideration of the potential pitfalls associated with each of them – CLICK…
Today’s article highlights “a low-risk, high-quality small biotech with high growth potential.” More specifically, this “is a revolutionary biotech company that uses tissue engineering to treat/repair sports-related injuries and severe burns” – and while it was negatively impacted this year by the canceling and delaying of elective surgeries due to COVID-19, the author outlines why rapid growth should return in…
Biotech bulls see a bright year ahead for the sector thanks to a range of catalysts outside of COVID. As today’s article explains, “Among the most closely tracked catalysts are the potential approval of Biogen Inc.’s experimental drug for Alzheimer’s disease, expectations for a rebound in deal-making activity, and innovations from gene therapy updates to next-generation cancer technologies.” For more…
“In light of all the focus on a coronavirus vaccine, most people tend to overlook the other happenings in the industry,” notes the author of today’s article. He reminds us that, even in the midst of a global pandemic, research has continued on treatments and drugs for cancers, genetic diseases, rare diseases and more – and he highlights three biotech…
With COVID-19 vaccine stocks Pfizer and Moderna receiving so much attention, the author of today’s article notes that “This leaves a lot of biotech stocks lacking the attention they deserve. While this is bad news for current holders of these stocks, it is an opportunity for new ones.” With this in mind, he proceeds to highlight three “under-loved” biotech stocks…
Which biotechs are the hottest acquisition targets heading into 2021 – and which large drugmakers are likely to seek to acquire them? Seventy-eight members of the biopharma investment community offered their opinions in a recent Bloomberg Intelligence survey – and today’s article outlines their biotech acquisition predictions. For more, CLICK HERE.
“With multiple potential blockbusters in development, and a track record that proves the company knows how to launch a new drug… [this] stock is probably worth the risk right now,” advises the author of today’s article in regards to the biotech he examines, which, having just launched its first rare disease drug last spring, could receive its fourth new drug…
While the small biotech company featured in today’s article is not working on solving the health problem of the day – COVID-19 – it is solving a major problem that affects one in eight couples and is more prevalent than diabetes, asthma and depression. And with the company having “a clear-cut mission, great management, and a history of revenue growth”,…
Small and midcap stocks – or “smidcaps” – have had a strong November, and the author of today’s article asserts that this strong performance will continue: “This group has been beaten and battered for so long that many people simply doubt the move. But this is a big mistake. I don’t know about the next few days ahead, but smidcaps…
What’s attractive about stocks with a market value around $1 billion? The author of today’s article explains that “At that size, a stock is small enough so that it hasn’t yet been “discovered” by a lot of Wall Street firms, but big enough to have some heft and staying power.” Each year he selects ten stocks hovering around the billion-dollar…